Related Experiment Videos
The placebo effect in cardiovascular disease
L Bienenfeld1, W Frishman, S P Glasser
1Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10461, USA.
Insights
Placebo treatments show a direct link to better outcomes in preventing myocardial infarction. Short-term placebo trials are safe for cardiovascular drug studies, even with ethical debates.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Placebo effects are documented in various cardiovascular conditions including systemic hypertension, angina pectoris, silent myocardial ischemia, congestive heart failure (CHF), and ventricular tachyarrhythmias.
- Compliance with placebo treatment correlates with positive clinical outcomes in myocardial infarction prevention.
- The safety of short-term placebo-controlled trials is established in angina pectoris drug studies.
Purpose of the Study:
- To review the established effects of placebo in cardiovascular diseases.
- To assess the safety and ethical considerations of placebo-controlled trials in cardiovascular drug evaluation.
- To emphasize the scientific value of placebo-controlled studies when life-saving treatments are not withheld.
Main Methods:
- Literature review of existing studies on placebo effects in cardiovascular diseases.
- Analysis of safety data from short-term placebo-controlled trials.
- Discussion of ethical frameworks for placebo use in clinical research.
Main Results:
- Placebo effects are well-characterized across multiple cardiovascular conditions.
- A direct relationship exists between adherence to placebo and favorable outcomes in myocardial infarction prevention.
- Short-term placebo-controlled trials are deemed safe and informative for cardiovascular drug development.
Conclusions:
- Placebo-controlled trials remain a scientifically valuable tool in cardiovascular research.
- The ethical challenges of placebo use are manageable when life-saving alternatives are available.
- Continued use of placebo-controlled studies is prudent for generating robust scientific evidence in cardiovascular drug evaluation.
Abstract:
The effect of placebo on the clinical course of systemic hypertension, angina pectoris, silent myocardial ischemia, CHF, and ventricular tachyarrhythmias has been well described. In the prevention of myocardial infarction, there appears to be a direct relation between compliance with placebo treatment and favorable clinical outcomes. The safety of short-term placebo-controlled trials has now been well documented in studies of drug treatment of angina pectoris. Although the ethical basis of performing placebo-controlled trials continues to be challenged in the evaluation of drugs for treating cardiovascular disease, as long as a life-saving treatment is not being denied it remains prudent to perform placebo-controlled studies for obtaining scientific information.